Hmcn2 Inhibitors
Chemical inhibitors of Hmcn2 target various aspects of extracellular matrix (ECM) interaction and remodeling. Marimastat, GM6001, and Batimastat are matrix metalloprotease (MMP) inhibitors that directly prevent the degradation of ECM components. Since Hmcn2 is involved in the organization and stabilization of the ECM, inhibiting MMPs can indirectly limit the influence of Hmcn2 on these processes. SB-3CT, which selectively inhibits MMP-2 and MMP-9, works in a similar fashion, focusing on the proteolytic activities that are integral to ECM turnover. NSC 405020 specifically inhibits MMP-14, a key enzyme in ECM remodeling, thus affecting the functional capacity of Hmcn2 to modulate the ECM structure.
In addition to the MMP inhibitors, other chemicals interfere with signaling pathways that are crucial for cell-ECM interactions where Hmcn2 plays a role. DAPT, a gamma-secretase inhibitor, impacts the Notch signaling pathway, which is closely associated with cell fate decisions and ECM interactions. PD98059 and U0126, inhibitors of the MAPK/ERK pathway, along with SP600125, an inhibitor of JNK, and SB202190, a selective inhibitor of p38 MAP kinase, all act to modulate the cellular responses to the ECM. These inhibitors can indirectly influence the role of Hmcn2 in cell differentiation and apoptosis, which are critical for ECM dynamics. LY294002, a PI3K inhibitor, and Y-27632, a selective inhibitor of ROCK, target other pathways essential for cell survival, angiogenesis, and cytoskeletal organization, respectively. These pathways are important for the mediation of Hmcn2's interactions with the ECM, influencing cell shape, motility, and ultimately the structural integrity of the ECM itself.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloprotease (MMP) inhibitor. Hmcn2 is involved in extracellular matrix (ECM) organization, and MMPs play a significant role in ECM degradation. By inhibiting MMPs, Marimastat can preserve ECM structure and potentially inhibit the functional role of Hmcn2 in ECM remodeling. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
GM6001, also known as Ilomastat, is an MMP inhibitor similar to Marimastat. It prevents the degradation of ECM components, thereby potentially inhibiting the activity of Hmcn2 which is involved in ECM stabilization and organization. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $179.00 $377.00 | 24 | |
Batimastat is another MMP inhibitor that impedes the breakdown of ECM. As Hmcn2 contributes to the maintenance and structure of the ECM, inhibiting MMPs with Batimastat could reduce the functional impact of Hmcn2 on ECM dynamics. | ||||||
SB-3CT | 292605-14-2 | sc-205847 sc-205847A | 1 mg 5 mg | $102.00 $388.00 | 15 | |
SB-3CT is a selective inhibitor of MMP-2 and MMP-9. It works by preventing the proteolytic activity of these MMPs, thereby influencing the ECM turnover, which is a process where Hmcn2 is implicated. The inhibition of MMPs could indirectly inhibit Hmcn2's role in ECM remodeling. | ||||||
NSC 405020 | 7497-07-6 | sc-477738 | 10 mg | $105.00 | ||
NSC 405020 specifically targets MMP-14, an enzyme involved in ECM remodeling and degradation. By inhibiting MMP-14, this chemical could diminish the functional capacity of Hmcn2 to influence the ECM structure. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a gamma-secretase inhibitor that can influence the Notch signaling pathway. Hmcn2 is believed to participate in cell-cell signaling within the ECM, and Notch signaling is pivotal in determining cell fate and ECM interactions. Inhibition by DAPT may alter the signaling environment that Hmcn2 is involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the mitogen-activated protein kinase (MAPK/ERK) pathway, which is involved in cell proliferation and differentiation, both processes in which the ECM plays a critical role. By inhibiting this pathway, PD98059 could indirectly inhibit the role of Hmcn2 in ECM-related signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. The PI3K pathway is involved in cell survival and angiogenesis, which are influenced by ECM interactions. Inhibiting PI3K could reduce the functional influence of Hmcn2 in ECM modulation and cellular responses to the ECM. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of ERK in the MAPK pathway. Given the role of the MAPK pathway in cell differentiation and ECM interactions, U0126 could indirectly inhibit the functional activities of Hmcn2 in the ECM. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK pathway. JNK contributes to apoptosis and inflammation, both of which can affect the ECM. Inhibiting JNK may thus indirectly inhibit Hmcn2's role in mediating ECM-related cell signaling. | ||||||